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Abstract 
 
We studied the safety and efficacy of 0 U, 50 U, 100 U, 150 U (five sites), 86 Usub and 100 Usub (three 
sites) botulinum toxin type A (BoNTA; BOTOX®; Allergan, Inc., Irvine, CA, USA) for the prophylaxis 
of chronic tension-type headache (CTTH). Three hundred patients (62.3% female; mean age 42.6 years) 
enrolled. For the primary endpoint, the mean change from baseline in the number of TTH-free days per 
month, there was no statistically significant difference between placebo and four BoNTA groups, but a 
significant difference favouring placebo vs. BoNTA 150 was observed (4.5 vs. 2.8 tension headache-free 
days/month; P = 0.007). All treatment groups improved at day 60. Although efficacy was not 
demonstrated for the primary endpoint, at day 90, more patients in three BoNTA groups had ≥50% 
decrease in tension headache days than did placebo (P ≤ 0.024). Most treatment-related adverse events 
were mild or moderate, and transient. BoNTA was safe and well-tolerated in the study.   
  
Introduction 
 
Tension-type headache (TTH) is one of the primary headache disorders—having an overall annual prev- 
alence as high as 38%—with 2% of patients affected on a daily or almost daily basis (1). Sensitization of 
afferents within peripheral tissues (e.g. muscles) by local nociceptive mediators can give rise to increased 
nociceptive afferent fibre activity, leading to central sensitization, and may be a pathogenic marker in 
chronic tension-type headache (CTTH) (2–8). The exact role of peripheral and central sensitization in 
CTTH is still unclear (8–10). 
 
At motor neurons, botulinum toxin type A (BoNTA; BOTOX®; Allergan, Inc., Irvine, CA, USA) inhibits 
exocytosis of acetylcholine from presynaptic nerve endings through proteolytic cleavage of a specific 
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target protein, SNAP-25 (synaptosomal protein) with a molecular weight of 25 kDa), that is essential for 
vesicle fusion with neuronal membranes leading to decreased muscle contractions (11). In preclinical 
studies, BoNTA has also been shown to block the release of nociceptive mediators such as substance P, 
glutamate, and calcitonin gene-related peptide (CGRP) at non-cholinergic, non-motor neurons via SNAP-
25 cleavage (11–14). Cui and colleagues have demonstrated that local peripheral injection of BoNTA 
significantly reduces formalin-induced nociceptive behaviour in rats in a dose-related manner with an 
absence of obvious muscle weakness (13). A  small, open-label preliminary study of the analgesic effects 
of BoNTA in humans found that while BoNTA did inhibit peripheral neuropeptide release from 
nociceptive nerve fibres, its analgesic effects were reported by the authors to be limited (15). These results 
may have been influenced by the model used in this study since an electrical stimulus was applied directly 
to stimulate the pain nerve. The BoNTA pretreatment was only able to inhibit the peripheral nociceptive 
peptide release (measured as neurogenic flare) in the volunteers. Since BoNTA does not cross the blood–
brain barrier and is not transported centrally by the nerve, there was no effect of BoNTA on hyperalgesia 
or allodynia elicited by electrical stimulation. Therefore, BoNTA would not have the ability to block 
electrically induced pain. In the preclinical studies, BoNTA was effective in situations where sufficient 
peripheral sensitization (i.e. formalin or capsaicin) could be achieved, so BoNTA may inhibit the 
peripheral release of nociceptive signals and thus reduce sensory input into the central nervous system 
(CNS) (12). Further clinical studies of this effect in humans are needed to confirm the results of preclinical 
studies.  
 
BoNTA modification of pain pathways may potentially inhibit the pain associated with headache 
disorders. The results of double-blind, placebo-controlled trials, open-label trials and retrospective chart 
reviews show mixed evidence of efficacy that focal injections of BoNTA significantly reduce the 
frequency, severity and disability associated with migraine, TTH and other types of headaches (16–30). 
The varying results may be due to patient selection, the number of BoNTA treatments administered, the 
injection protocol employed or the dosage range used.  
 
The purpose of this trial was to evaluate the safety and efficacy of a single BoNTA treatment in five active 
treatment groups compared with placebo for the prophylactic treatment of CTTH. 
 
Methods  
 
Objective  
 
The objective of this study was to examine the safety and efficacy of a single treatment of BoNTA for the 
prophylactic treatment of CTTH.  
 
Study design  
 
This was a double-blind, randomized, placebo-controlled, parallel-group, multicenter study conducted 
from 4 January 2000 to 28 February 2001. There were 22 North American study centers (one in Canada 
and 21 in the USA) and seven European study centers (three in Germany, two in the UK, one in Belgium 
and one in Denmark). Prior to enrolment and subsequent randomization to BoNTA or placebo, patients 
entered a 30-day baseline period during which they were screened for eligibility. During the baseline 
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period patients were required to record data capturing specified characteristics of their headache episodes 
and headache medication use using a paper diary. All eligible subjects who continued to meet eligibility 
criteria at the end of a 30-day screening baseline period were randomized to one of six treatment groups.  
 
Participant characteristics 
  
Eligible participants were men or women aged 18– 65 years with a history of CTTH as defined by 
International Headache Society criteria (31) (Key inclusion and exclusion criteria are outlined in Table 1).  
 
The investigator could discontinue participants prematurely from the study for adverse events, protocol 
violations, lack of efficacy, or administrative reasons (e.g. inability to continue, lost to follow-up).  
 
Patients taking prophylactic headache medications were required to have been on a stable dose for at least 
3 months prior to enrolment and had to maintain a stable dose throughout the study. The use of any 
concurrent prescription or over-the-counter medication and the reason for taking it were recorded.  
 
Intervention and protocol  
 
Each vial of BOTOX
® (Allergan, Inc.) was stored in a freezer between −20°C and −5°C before use and 
contained 100 U of botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a 
sterile, vacuum-dried form without a preservative. BOTOX was reconstituted with 3 ml of the diluent, 
0.9% sterile saline (without preservative). Reconstituted solutions were stored in a refrigerator until use 
(within 4 h). To maintain the blinding of the study and the investigator (injector) and other staff involved 
in assessing or reporting on the subject, an individual not involved with these activities was identified at 
each study center to perform the dilutions and draw up the study medication.  
 
At the injection visit (day 0), patients received a single treatment of 10 intramuscular injections of 
BOTOX, placebo or both in five muscle groups (Fig. 1, Table 2). Depending on the muscle area, 0.20–
0.80 ml (3.3–40 U) was injected. Three treatment groups received BOTOX (50 U, 100 U or 150 U) 
distributed in all five muscle groups; two treatment groups received BOTOX (either 86 U or 100 U) dis- 
tributed in three muscle groups (and placebo in two muscle groups); and one group received placebo in 
all five muscle groups (Table 2). Total BOTOX doses were 50 U, 86 Usub, 100 U, 100 Usub and 150 U 
(‘sub’ identifies the groups in which only three muscle groups received active treatment); the number of 
BOTOX U per muscle for each treatment group was fixed. Post-injection follow-up evaluations were 
scheduled on days 30, 60, 90 and 120.  
 
At each study visit, participants were given a week paper diary and instructed to complete it on a daily 
basis throughout the study. Patients recorded the occurrence, severity, maximum severity and location of 
TTH; associated headache symptoms (nausea, vomiting, increased sensitivity to light and/or noise, and 
worsening head pain with physical activity); percentage of each day with headache, as calculated from the 
hours awake with headache as a proportion of those hours; headache medications with dose and time of 
dose; and the occurrence of non-TTH. Patients were administered the Headache Pain Specific Quality of 
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Life Questionnaire, the Tension-Type Headache Impact Questionnaire and the SF-36 Health Survey to 
evaluate the impact of treatment. The diaries were collected at the scheduled monthly study visits.
This study was conducted in compliance with institutional review board regulations in each participating 
country, the Declaration of Helsinki, informed consent regulations of each participating country, the 
recommendations of the International Headache Society for studies in the prophylactic treatment of 
CTTH, and the International Conference on Harmonization guideline for Good Clinical Practice.  
 
Outcome measures  
 
Efficacy  
 
The primary efficacy variable was the mean change from baseline in the number of TTH-free days per 
month for the 30 days prior to day 60 (postinjection) recorded by the patient in the paper diary. The 
clinical criterion for effectiveness was a 3 days/month difference between treatment groups in the mean 
change from baseline for the number of TTH-free days.  
 
Secondary efficacy measures included the percentage of patients reporting at least a 50% decrease in TTH 
days; percentage of the day with headache, as calculated from the hours awake with headache as a 
proportion of the hours awake; average of headache severity, as recorded in the patient diary; and 
concurrent headache medication usage.  
 
Information from measures collected during office visits included the subject’s response to treatment 
[rated on a 9-point Global Assessment Scale from −4 (very marked worsening) to +4 (clearance of signs 
and symptoms)]; the subject’s rating of worst, least and usual TTH-associated pain as measured on an 11-
point scale (0 = no pain to 10 = pain as bad as can be); and the subject’s score on a Beck Depression 
Inventory. Other efficacy measures documented in the patient’s diary included days of current acute 
headache medication usage per 30-day interval, average maximal headache severity per 30-day interval, 
presence/absence of associated headache symptoms and non-TTH days per 30-day interval.  
 
Safety  
 
Adverse events. All reported adverse events were recorded, with information regarding the date of onset, 
resolution date (if applicable), severity (mild, moderate or severe), duration, frequency, relationship to 
study treatment, action taken regarding study treatment, treatment required (if any), and outcome included. 
The relationship between an adverse event and study treatment was assessed by the investigator as none, 
possible, probable or definite. A serious adverse event was defined as one that was fatal, life threatening, 
or permanently disabling, or that resulted in hospitalization or prolongation of existing hospitalization.  
 
Laboratory variables. Blood specimens were collected at the first screening visit and the last scheduled 
visit (day 120 or study exit). Standard blood chemistry, electrolyte panel and haematology analyses were 
performed and reported.  
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Physical examination and vital signs. A physical examination was performed, and height, weight, blood 
pressure, pulse rate and body temperature were measured at the first screening visit and the last scheduled 
visit (day 120 or study exit). At all other study visits, pulse rate and blood pressure were measured.  
 
Statistical analyses  
 
Analyses were performed on data from the intent-to-treat population, which included all randomized 
subjects. Subjects were analysed as randomized, regardless of which treatment they actually received, for 
all except safety variables. For safety variables, subjects were analysed as actually treated. All tests were 
two-sided and utilized a type I error of α= 0.05 to determine statistical significance, except that treatment-
by-subgroup interactions were examined at the 0.10 level.  
A key variable (mean change from baseline in TTH-free days) and visit (day 60) were identified. For the 
key variable and visit, protection against multiple comparison errors was accomplished by examining P-
values for significance between any of the five BoNTA groups and placebo only if the calculated P-value 
was <0.05/5 = 0.01 (Bonferroni method). Other variables, visits and pairwise treatment comparisons were 
considered supportive.  
 
Data were summarized with descriptive statistics and/or response frequencies, including sample size, 
mean, standard deviation, median, minimum and maximum. For variables with ordered response 
categories and variables with a continuous response range, simultaneous comparisons among all 
treatments were done with the Kruskal–Wallis test (via analysis of variance of ranks). Comparisons 
between pairs of treatment groups were done with the Wilcoxon rank sum tests, even if the among-
treatment results were not significant. For the continuous variables, if the responses appeared to be 
normally distributed (via the Shapiro–Wilk statistic), one-way analysis of variance methods were 
considered to improve the efficiency of the inferential test. If there were significant baseline differences 
between the treatments in a primary or secondary efficacy variable, a baseline covariate was included in an 
analysis of covariance of the variable. For binomial data, comparisons between treatment groups were 
done with χ
2 
tests, 2 × 6 among-group comparisons, and 2 × 2 pairwise treatment comparisons. If the 
expected value of any cell in a table was <5, the affected distribution was tested with Fisher’s exact test. 
 
Results  
 
Patient demographics  
 
The screening included 429 patients, 300 of whom [187/300 (62.3%) female; mean age 42.6 years (range 
18–65 years)] were eligible for participation and enrolled. There were no significant demographic 
differences between the treatment groups. Forty-nine patients were randomized to BoNTA 150 U, 51 
patients to BoNTA 100 U, 52 patients to BoNTA 100 Usub, 51 patients to BoNTA 86 Usub, 47 patients to 
BoNTA 50 U and 50 patients to placebo  (Table 3). A total of 279/300 patients (93%) completed the 
study. The most common reason for discontinuation was loss to follow-up [13/300 (4.3%)]. Seven BoNTA 
patients discontinued the trial because of lack of efficacy. Of these patients, three were in the 150 U 
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treatment group, two were in the 100 Usub treatment group, one was in the 86 Usub treatment group and 
one was in the 50 U treatment group. One patient in the 100 Usub treatment group discontinued 
participation for other (personal) reasons. No patient discontinued the study due to adverse events.  
 
Headache history and medication use  
 
All patients had a diagnosis of CTTH. The mean time since onset of CTTH was 14.7 years (range 0– 54 
years) and the mean age at onset was 28.3 years (range 1–61 years). There were no significant differences 
between the treatment groups in the CTTH history. Patients recorded a mean frequency of 23.0, 23.9, 23.8, 
22.8, 25.5, and 25.2 TTH days per month in the BoNTA 150 U, 100 U, 100 Usub, 86 Usub, 50 U and 
placebo groups, respectively (Table 3). In addition to having CTTH, 95/300 (31.6%) patients reported 
having at least one migraine per month. Patients experienced a mean of 0.7 migraines per month with a 
mean duration of 1.2 days per month. A total of 13/300 enrolled patients had less than 15 headache days 
per month at baseline (seven in the 150 U group; two each in the 100 U, 100 Usub and 86 Usub groups) 
and should not have been enrolled as per the protocol criteria. Overall, patients reported a mean headache 
duration of 12.4 h per day. Most patients (87.9%) reported taking analgesic and/or prophylactic 
medications including aspirin, ibuprofen, acetaminophen, acetaminophen plus codeine, non-steroidal anti-
inflammatory drugs, β-blockers, antidepressants and anticonvulsants for TTH pain. A total of 98 patients 
(32.7%) reported taking concomitant prophylactic headache medications. Patients in the BoNTA 150 U, 
100 U, 100 Usub, 86 Usub, 50 U and placebo groups used acute headache pain medication for a mean of 
8.7, 10.3, 9.8, 11.9, 8.8 and 8.5 days, respectively, during the 30-day baseline period. There were no 
statistically significant differences between the treatment groups in their use of acute headache pain 
medication at baseline. There were 111/300 patients (37%) who used headache pain medication for 16 or 
more days during the baseline period. At baseline, most patients [195/300 (65%)] did not report associated 
symptoms with their headaches; however, the rest [105/300 (35%)] reported one or more associated 
symptoms with some of their headaches. These symptoms included sensitivity to light [68/300 (22.7%)], 
sensitivity to sound [49/300 (16.3%)], nausea [15/300 (5%)] and vomiting [2/300 (0.7%)]. Pain associated 
with TTH was most often reported as bilateral [182/ 300 (60.7%)] and localized to either the front of the 
head [202/300 (67.3%)] or the back of the head [161/ 300 (53.7%)]. According to the investigator 
assessment, patients in the 100 U group (43.1%) had a significantly higher incidence of pain in the 
cervical region compared with patients in the other groups (14.0–29.8%; P = 0.015).  
 
Efficacy  
 
Primary variable: mean change from baseline in the number of TTH-free days  
At baseline, two of the five BoNTA treatment groups, BoNTA 100 U (6.5 days; P = 0.001) and 86 Usub 
(5.3 days; P = 0.008), had a significantly higher mean frequency of headache-free days (3.3 days) than the 
placebo group  (Table 4). For the primary endpoint, there was no difference between placebo and four of 
the BoNTA groups (50 U, 100 U, 86 Usub and 100 Usub) but a statistically significant difference favoring 
placebo compared with the BoNTA 150 U group was observed (4.5 vs. 2.8 tension headache-free days per 
month) (Fig. 2).  All groups demonstrated improvement at the day 60 primary endpoint. 
 
Secondary variables  
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Reduction of ≥50% of TTH days. No significant differences were found in the number of patients reporting 
a decrease of 50% or more headache days at day 60, the primary endpoint. However, at day 90, 
significantly larger percentages of patients in the BoNTA 100 U group [15/47 (31.9%); P = 0.017], the 
100 Usub group [15/49 (30.6%); P = 0.024] and the BoNTA 86 Usub group [15/47 (31.9%); P = 0.017] 
reported a 50% decrease in TTH days compared with the placebo group [6/50 (12.0%)]  (Fig. 3). 
 
 
Percentage of the day with headache.  There were no significant differences at day 60 in the percentage of 
the day with headache, calculated from hours awake and hours awake with headache as reported in the 
patient diary.  The mean decrease from baseline was -6.8%, -3.0%, -6.5%, -4.0%, -5.0% and -4.7% for 
BoNTA 150 U, 100 U, 100 Usub, 86 Usub, 50 U and placebo groups, respectively. 
 
Average usual headache severity.  There were no significant differences in the average usual headache 
severity at any time point.  At day 60, the mean decrease was -0.1, -0.1, -0.2, -0.2, -0.2, and -0.1 for 
BoNTA 150 U, 100 U, 100 Usub, 86 Usub, 50 U and placebo groups, respectively. 
 
 
Other efficacy measures  
 
At day 60, fewer patients in the BoNTA 150 U group reported a decrease of three or more TTH days 
compared with the BoNTA 86 Usub group [13/48 (27.1%) vs. 27/47 (57.4%); P = 0.003]. There were no 
significant differences between placebo and any BoNTA group in the other efficacy measures (subject’s 
rating of headache pain, treatment assessment, global assessment, Beck Depression Inventory, days of 
concurrent headache medication usage, average maximal headache severity, associated headache 
symptoms and non-TTHs) at day 60 or any other follow-up visit. A decrease in phonophobia, photophobia 
(except BoNTA 50 U) and headache symptoms worsening with physical activity was noted for all groups. 
There were no significant differences between the groups in the Headache Pain Specific Quality of Life 
Questionnaire, the Tension-Type Headache Impact Questionnaire, and the SF-36 Health Survey (at day 
60). There were no notable findings between the groups in the subgroup efficacy analyses.  
 
Safety  
 
Adverse events were reported for 61.7% (29/47) of BoNTA 150 U patients, 64.7% (33/51) of BoNTA 100 
U, 63.5% (33/52) of 100 Usub, 54.9% (28/51) of BoNTA 86 U, 51.0% (25/49) of BoNTA 50 U and 
52.0% (26/50) of placebo patients. The most frequently reported adverse events across all treatment 
groups were respiratory infection [10.7% (32/300)], neck pain [8.0% (24/300)] and muscular weakness 
[7.7% (23/300)]. Among 300 patients there were 41 adverse events reported as severe. Severe adverse 
events included seven, 11, five, four, seven and seven for the BoNTA 150 U, 100 U, 100 USub, 86 USub, 
50 U and placebo groups, respectively.  
 
Treatment-related adverse events were reported for 32.0% (96/300) of patients overall. There were no 
differences among the groups in the incidence of subjects reporting treatment-related adverse events 
(Table 5). The most frequently reported treatment-related adverse events were muscular weakness [20/ 
300 (6.7%)] and neck pain [16/300 (5.3%)]. There were no significant differences between any BoNTA 
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group and placebo in the incidence of treatment-related adverse events except the overall incidence of the 
100 U group [23/51 (45.1%) vs. 11/50 (22.0%); P = 0.014]. A consistent dose-response for these 
treatment-related adverse events was not apparent, but the BoNTA 100 U group did report the greatest 
incidence of muscular weakness, neck rigidity, neck pain, headache and pain. Most treatment-related 
adverse events were either mild or moderate in severity and transient in nature, and most patients had 
recovered without sequelae at the time that the study ended.  
 
There was no significant difference in the analysis of all BoNTA groups combined vs. placebo in the 
incidence of all adverse events or treatment-related adverse events. There were no clinically relevant 
differences among the groups in changes from screening to study exit for laboratory variables or vital 
signs. No subject died during the study. The five serious adverse events were worsening of headache, re-
dislocation of left shoulder, chest pain, palpitation (100 U group) and emotional lability (50 U). None of 
the serious adverse events was considered treatment related. 
 
Discussion  
 
The results of this clinical study suggest that BoNTA is a safe, well-tolerated intervention in patients with 
CTTH. No discontinuations due to adverse events occurred, nor were any treatment-related serious 
adverse events reported. The BoNTA patients, especially those treated with 100 U (but not those treated 
with 150 U) did have a greater percentage of transient, treatment-related, muscular weakness and neck 
pain, which are known to be associated with BoNTA injections.  
 
As a result of this intervention most patients evaluated in this study had more TTH-free days. The efficacy 
of BoNTA in the prophylactic treatment of CTTH compared with a placebo treatment was not  
confirmed in this study at day 60, the primary efficacy endpoint. However, at day 90 there was a 
significant effect of BoNTA treatment on the percentage of patients reporting a 50% decrease in headache 
days for several BoNTA dose groups, suggesting that perhaps a longer primary endpoint than 60 days may 
be warranted. The results of secondary and other efficacy measures did not show that BoNTA was 
significantly more effective than placebo, although improvement in most secondary and other efficacy 
measures was observed. The ability to differentiate BoNTA from placebo may have been confounded due 
to the uneven randomization (32) or due to the fact that patients were allowed to take acute headache pain 
medication as needed to treat their headaches, thereby potentially aborting or diminishing their headache 
characteristics.  
 
BoNTA has demonstrated antinociceptive activity in patients with cervical dystonia, spasticity and chronic 
musculoskeletal pain disorders in clinical trials (33–37), suggesting that BoNTA may have analgesic 
effects. BoNTA inhibition of the release of nociceptive molecules has been demonstrated in several 
preclinical studies (12–14) and BoNTA administration has been shown to attenuate pain behaviour in a rat 
model (13). These effects have yet to be demonstrated in humans (15). BoNTA efficacy as prophylactic 
treatment of TTH has been assessed in several small controlled trials, but the evidence of a treatment 
effect has thus far been mixed or lacking (17, 23, 25, 27, 30, 38). The reasons for the lack of efficacy of 
BoNTA treatment of CTTH in this trial may be related to the injection protocol, the BoNTA dosage range, 
the patient population or ineffectiveness in this patient population.  
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Injection protocol  
 
The injection protocol of this trial followed a fixed-site approach for TTH. Blumenfeld and colleagues  
(39) recommend a follow-the-pain approach for BoNTA treatment of TTH injecting the frontalis  
(2.5 U each, five sites on each side), temporalis (2.5 U each, four sites on each side), occipitalis (2.5–5 U 
on each side), trapezius (7.5–15 U on each side), semispinalis capitis (7.5–15 U on each side) and/or 
splenius capitis muscles, as deemed appropriate (21).  
 
The current study protocol did not include occipitalis injections and it did not use as many sites for 
BoNTA in various muscle groups (21, 26) (Table 2). With 60–75% of patients describing frontal head 
pain and 50–60% of patients describing pain in the back of the head, the addition of more frontalis 
injection sites, the addition of occipital injection sites and an increase in the total BoNTA U injected in 
these sites might also have had an impact on BoNTA efficacy. Only 147/300 patients (the BoNTA 50, 100 
and 150 U groups) received BoNTA injections into all five muscle sites. 
 
BoNTA dosage range  
 
Recent large, randomized, placebo-controlled BoNTA studies in patients with chronic headache disorders 
suggest that repeated BoNTA treatment between 105 U and 260 U, a higher dose range than those used in 
this study, may lead to better results (28, 29), although there are no such indications in the present study as 
fairly low doses of 100 U or 86 U demonstrated a better treatment effect than 150 U.  
 
Patient population  
 
Given that a large number of patients in this study reported concurrent migraine symptoms, such as 
sensitivity to light and sound, nausea and vomiting, and the numbers of patients reporting migraine 
headaches (95/300), it is likely that the patients in this study were not suffering exclusively from CTTH 
but also had coexisting infrequent migraine headaches similar to other TTH populations. In addition, the 
patients in this study were required to be on stable doses of prophylactic headache medications for at least 
3 months prior to the initiation of BoNTA treatment and could continue their prophylactic regimen 
throughout the course of the trial. The additional effect of concurrent prophylactic headache medication 
could have confounded the ability to assess a BoNTA treatment effect. 
 
Conclusions  
 
BoNTA treatment of CTTH in a dose range of 50 U to 150 U was shown to be safe and well tolerated. For 
tension headache-free days per month, all groups improved at the day 60 primary endpoint. There was no 
statistically significant difference between placebo and four BoNTA groups, but a significant difference 
favoring placebo vs. BoNTA 150 U was observed. At day 90, significantly more patients reported a 50% 
decrease in headache days in several BoNTA groups, suggesting that a longer period of evaluation may be 
needed to see a treatment effect. The failure of BoNTA to demonstrate efficacy in this trial may be related 
to the injection protocol, the BoNTA dosage range, the patient population, the use of concomitant 
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prophylactic headache medication or a lack of a clinically relevant effect in CTTH. BoNTA may not be an 
effective prophylactic treatment of CTTH, but further study may provide insight into appropriate study 
parameters and a possible treatment effect.  
 
Dosing and results reported in this study are specific to the formulation of botulinum toxin type A 
manufactured by Allergan, Inc. (Irvine, CA, USA). The Allergan, Inc. formulation is not interchangeable 
with other botulinum toxin products and cannot be converted by using a dose ratio.  
 
 
BOTOX CTTH Study Group  
 
Andrew Blumenfeld, MD (California); Roger Cady, MD (Missouri); Joanna Cooper, MD (California); 
James Couch, MD (Oklahoma); Seymour Diamond, MD (Illinois); Hans-Christoph Diener, MD 
(Germany); Marek J. Gawel, MD (Canada); Peter Goadsby, MD, PhD (UK); Jerome Goldstein, MD 
(California); V. Daniel Kassicieh, DO (Florida); Jack Klapper, MD (Colorado); Ninan Mathew, MD 
(Texas); Alexander Mauskop, MD (New York); Volker Pfaffenrath, MD (Germany); Sid Rosenblatt, MD 
(California); Joel Saper, MD (Michigan); Jack Scariano, MD (Tennessee); Jean Schoenen, MD (Belgium); 
Elliott Schulman, MD (Pennsylvania); Fred Sheftell, MD (Connecticut); Timothy Smith, MD (Missouri); 
Egilius Spierings, MD, PhD (Massachusetts); Stuart Stark, MD (Virginia); Timothy Steiner, MB, PhD 
(UK); Paul Winner, DO (Florida).  
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Figure 1  
Location of injection sites. Adapted, with permission, from Nucleus Medical Art 
(http://www.nucleusinc.com).  
 
 
 
 
Figure 2  
Mean change from baseline in the number of tension-type headache-free days at day 60.  
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Figure 3   
Percentage of patients with a decrease of 50% or more in tension-type headache days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  
Key inclusion and exclusion criteria 
 
Key inclusion criteria  Key exclusion criteria  
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Patients who experienced a stable 
headache frequency and severity 
for 6 months prior to and including 
the screening period  
 
Patients who for 6 months prior to and 
including the screening period 
experienced an average headache 
frequency of 15 days or more per 
month, as confirmed  by their 
history and by their headache diary  
 
Participants who were able to 
distinguish tension-type headaches 
from non-tension-type headaches 
and follow study instructions  
Any medical condition or the use of any agent that may put the 
participant at risk with exposure to BoNTA (e.g. neuromuscular 
disorders, aminoglycoside antibiotics, curare-like agents, or other 
agents that might interfere with neuromuscular function)  
 
Symptomatic medication overuse (defined as use of acute headache 
analgesics on more than 15 days  per month and in excess of 100 
aspirin-equivalent tablets per month or use of butalbital or 
ergotamine combinations on more than 3 days per week or regular 
use of narcotic analgesics or excessive use of caffeine-containing 
products)  
 
More than 1 migraine headache per month for the 6 months prior to 
screening or during the 1-month screening period or the presence 
of cluster headache or cranial neuralgias including postherpetic 
neuralgia  
 
Consistently refractory to multiple acute therapies for the treatment of 
CTTH  
 
On prophylactic headache medications for less than 3 months 
immediately prior to the day-30 visit  
 
Injection of anaesthetics or steroids into the muscles to be injected in the 
month immediately prior to the day-30 visit  
 
Previous therapy with botulinum toxin of any serotype  
 
Women who were pregnant, nursing, or planning a pregnancy during the 
study or who are unable or unwilling to use a reliable form of 
contraception during the study  
 
A condition or situation that, in the investigator ’s opinion, may have put 
the patient at significant risk, confound the study results, or 
significantly interfered with the patient participating in the study 
 
 
 
 
 
 
 
 
 
 
 
Table 2  
Injection protocol  
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                               Muscle  
                                                        Sternocleido- 
 Frontalis  mastoid  Upper trapezius  Splenius capitis  Anterior temporalis  
Treatment group  (2 sites)  (2 sites)  (2 sites)  (2 sites)  (2 sites)  
BoNTA 50 U  3.3 U  13.3 U  12 U  12 U  9.3 U  
 0.20 ml  0.80 ml  0.72 ml  0.72 ml  0.56 ml  
BoNTA 86 
Usub  10 U  40 U  36 U  0.0 U  0.0 U  
 0.20 ml  0.80 ml  0.72 ml  0.72 ml  0.56 ml  
BoNTA 100 U  6.7 U  26.7 U  24 U  24 U  18.7 U  
 0.20 ml  0.80 ml  0.72 ml  0.72 ml  0.56 ml  
BoNTA 100 
Usub  0 U  0 U  36 U  36 U  28 U  
 0.20 ml  0.80 ml  0.72 ml  0.72 ml  0.56 ml  
BoNTA 150 U  10 U  40 U  36 U  36 U  28 U  
 0.20 ml  0.80 ml  0.72 ml  0.72 ml  0.56 ml  
Placebo  0 U  0 U  0 U  0 U  0 U  
 0.20 ml  0.80 ml  0.72 ml  0.72 ml  0.56 ml  
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Table 3  
Tension-type headache (TTH) characteristics at baseline 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Published version available at doi:10.1111/j.1468-2982.2006.01114.x  
Silberstein SD, Göbel H, Jensen R, Elkind AH, DeGryse R, Walcott JMcM & Turkel C. Botulinum toxin type A in the prophylactic treatment of chronic 
tension-type headache: a multicenter, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26:790–800. Copyright © 
Blackwell Publishing Ltd.  
 
 
Table 4  
Tension-type headache-free days at baseline
________________________________________________________________ 
P-value 
vs. placebo 
Treatment group   Mean   Median      at baseline 
_________________________________________________________________________________ 
  
BoNTA 150 U    5.4   2.0   0.065 
BoNTA 100 U    6.5   6.0   0.001* 
BoNTA 100 Usub   5.3   3.0   0.027 
BoNTA 86 Usub   5.3   4.5   0.008* 
BoNTA 50 U    4.8   2.0   0.133 
Placebo    3.3   0.0   -- 
________________________________________________________________
   *P ≤0.01. 
 
 
 
 
 
Table 5  
Treatment-related adverse events reported in at least 3% of patients in any treatment group, by number 
(%) of subjects 
 
                                                  BoNTA 
150 U 100 U 100 Usub 86 Usub 50 U Placebo 
Preferred term n = 47 n = 51 n = 52 n = 51 n = 49 n = 50 
Overall  13 (27.7)  23 (45.1)  16 (30.8)  17 (33.3)  16 (32.7)  11 (22.0)  
   Muscular weakness  3 (6.4)  10 (19.6)  2 (3.8)  3 (5.9)  1 (2.0)  1 (2.0)  
   Neck rigidity  1 (2.1)  5 (9.8)  0 (0.0)  0 (0.0)  2 (4.1)  0 (0.0)  
   Neck pain  3 (6.4)  4 (7.8)  2 (3.8)  3 (5.9)  3 (6.1)  1 (2.0)  
   Headache  0 (0.0)  4 (7.8)  2 (3.8)  2 (3.9)  2 (4.1)  2 (4.0)  
   Pain  1 (2.1)  4 (7.8)  3 (5.8)  0 (0.0)  0 (0.0)  1 (2.0)  
   Dizziness  0 (0.0)  4 (7.8)  1 (1.9)  0 (0.0)  1 (2.0)  0 (0.0)  
   Injection-site pain  1 (2.1)  1 (2.0)  1 (1.9)  1 (2.0)  1 (2.0)  3 (6.0)  
   Dysphagia  0 (0.0)  1 (2.0)  0 (0.0)  3 (5.9)  0 (0.0)  0 (0.0)  
   Paraesthesia  0 (0.0)  0 (0.0)  1 (1.9)  3 (5.9)  0 (0.0)  0 (0.0)  
   Asthenia  0 (0.0)  2 (3.9)  0 (0.0)  3 (5.9)  2 (4.1)  0 (0.0)  
   Hypertonia  2 (4.3)  0 (0.0)  2 (3.8)  1 (2.0)  0 (0.0)  0 (0.0)  
   Nausea  0 (0.0)  0 (0.0)  0 (0.0)  1 (2.0)  2 (4.1)  0 (0.0)  
   Pharyngitis  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)  2 (4.1)  0 (0.0)  
   Injection-site burning  1 (2.1)  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)  2 (4.0)  
 
 
 
